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Cellular/Molecular
Specific Targeting of Pro-Death NMDA Receptor Signals with
Differing Reliance on the NR2B PDZ Ligand
Francesc X. Soriano,1,2* Marc-Andre Martel,1,2* Sofia Papadia,1,2 Anne Vaslin,3 Paul Baxter,1,2 Colin Rickman,1
Joan Forder,4Michael Tymianski,4 Rory Duncan,1Michelle Aarts,5 Peter G. H. Clarke,3David J. A. Wyllie,1,2 and
Giles E. Hardingham1,2
Centres for 1Integrative Physiology and 2Neuroscience Research, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom, 3De´partement de Biologie
Cellulaire et de Morphologie, Universite´ de Lausanne, CH-1015 Lausanne, Switzerland, 4Department of Neurosurgery, Toronto Western Hospital, Toronto,
Ontario, Canada M5T 2S8, and 5Centre for the Neurobiology of Stress, University of Toronto at Scarborough, Scarborough, Ontario, Canada M1C 1A4
NMDA receptors (NMDARs) mediate ischemic brain damage, for which interactions between the C termini of NR2 subunits and PDZ
domain proteins within the NMDAR signaling complex (NSC) are emerging therapeutic targets. However, expression of NMDARs in a
non-neuronal context, lacking many NSC components, can still induce cell death. Moreover, it is unclear whether targeting the NSC will
impairNMDAR-dependent prosurvival andplasticity signaling.We show that theNMDARcanpromotedeath signaling independently of
the NR2 PDZ ligand, when expressed in non-neuronal cells lacking PSD-95 and neuronal nitric oxide synthase (nNOS), key PDZ proteins
that mediate neuronal NMDAR excitotoxicity. However, in a non-neuronal context, the NMDAR promotes cell death solely via c-Jun
N-terminal protein kinase (JNK), whereas NMDAR-dependent cortical neuronal death is promoted by both JNK and p38. NMDAR-
dependent pro-death signaling via p38 relies on neuronal context, although death signaling by JNK, triggered bymitochondrial reactive
oxygen species production, does not. NMDAR-dependent p38 activation in neurons is triggered by submembranous Ca2, and is
disrupted by NOS inhibitors and also a peptide mimicking the NR2B PDZ ligand (TAT-NR2B9c). TAT-NR2B9c reduced excitotoxic
neuronal death and p38-mediated ischemic damage, without impairing anNMDAR-dependent plasticitymodel or prosurvival signaling
toCREBorAkt. TAT-NR2B9cdidnot inhibit JNKactivation, and synergizedwith JNK inhibitors to ameliorate severe excitotoxicneuronal
loss in vitro and ischemic cortical damage in vivo. Thus, NMDAR-activated signals comprise pro-death pathways with differing require-
ments for PDZ protein interactions. These signals are amenable to selective inhibition, while sparing synaptic plasticity and prosurvival
signaling.
Keywords:NMDA receptor; neuronal death; PDZ domains; stroke; calcium;mitochondria; neuroprotection; nitric oxide; protein kinase;
signal transduction
Introduction
A high and prolonged rise in the extracellular glutamate concen-
tration kills central neurons (Olney, 1969). During an ischemic
episode, glutamate levels build up as a result of synaptic release
and impaired and/or reversed uptake mechanisms (Camacho
andMassieu, 2006), which induce Ca2-dependent cell death via
excessive activation of NMDA glutamate receptors (NMDARs)
(Arundine and Tymianski, 2004). ExcessiveNMDAR activity can
lead to cell death in other acute episodes such as mechanical
trauma, and may contribute to neurodegeneration in Alzhei-
mer’s disease (Chohan and Iqbal, 2006). The destructive effects of
excessive NMDAR activity are in contrast to the prosurvival ef-
fects of physiological NMDAR activity (Ikonomidou and Turski,
2002; Hardingham and Bading, 2003; Papadia and Hardingham,
2007). Elimination of NMDAR activity in vivo causes widespread
apoptosis and enhances trauma-induced injury in developing
neurons (Gould et al., 1994; Ikonomidou et al., 1999; Adams et
al., 2004). In the adult CNS, NMDAR blockade exacerbates neu-
ronal loss when applied after traumatic brain injury and during
ongoing neurodegeneration (Ikonomidou et al., 2000), and pre-
vents the survival of newborn neurons in the adult dentate gyrus
(Tashiro et al., 2006). Molecular mechanisms of synaptic
NMDAR-dependent neuroprotection are beginning to be eluci-
dated (Hetman and Kharebava, 2006; Papadia and Hardingham,
2007; Zhang et al., 2007; Papadia et al., 2008). Thus, responses of
neurons to NMDAR activity follow a bell-shaped curve: both too
much and too little are potentially harmful. The central role of the
NMDAR in CNS physiology offers an explanation as to why clin-
ical treatment of stroke with NMDAR antagonists has failed be-
cause of poor tolerance and efficacy (Ikonomidou and Turski,
2002; Muir, 2006). It would be desirable to block pro-death
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NMDAR signaling in stroke, without affecting prosurvival sig-
naling or indeed synaptic plasticity, many forms of which are
mediated by NMDAR activation.
In neurons, Ca2 influx through NMDARs promotes cell
deathmore efficiently than through other Ca2 channels (Tymi-
anski et al., 1993; Arundine and Tymianski, 2004), suggesting
that proteins responsible for Ca2-dependent excitotoxicity re-
side within the NMDAR signaling complex (NSC). A role for the
NSC in mediating NMDAR-dependent death was shown in the
case of the PDZ proteins neuronal nitric oxide synthase (nNOS)
and PSD-95 (Aarts et al., 2002). PSD-95 is linked to the
C-terminal PDZ ligand of NR2, and also binds to nNOS. When
the interaction of NR2B and PSD-95 is disrupted, the NMDAR
becomes uncoupled from nNOS activation, reducing (but not
eliminating) NMDAR-dependent excitotoxicity (Aarts et al.,
2002). The important role of nNOS and PSD-95 above any other
PDZ proteins in mediating NMDAR-dependent excitotoxicity
was recently demonstrated (Cui et al., 2007).
The attractiveness of the NSC as a therapeutic target is ques-
tioned by two issues. First, it is not clear whether NSC compo-
nents can be disrupted without affecting prosurvival or plasticity
signaling. Second, NMDAR-dependent cell death can be recon-
stituted in non-neuronal cells lacking theNSC simply by express-
ing NMDARs (Cik et al., 1993; Anegawa et al., 2000), which
shows that certain NMDAR-induced death pathways do not re-
quire the NSC.
We have investigated both these issues with the aim of devel-
oping an effective anti-excitotoxic strategy that spares prosur-
vival and plasticity signaling, focusing on two key mediators of
excitotoxicity: the stress-activated protein kinases (SAPKs) p38
mitogen-activated protein kinase (MAPK) and c-JunN-terminal
protein kinase (JNK) (Kawasaki et al., 1997; Borsello et al., 2003;
Rivera-Cervantes et al., 2004).We find that these death pathways
have differing requirements for the NSC and can be disrupted to
great effect in vivo and in vitro without impacting prosurvival
signaling or a model of NMDAR-dependent synaptic plasticity.
Materials andMethods
Neuronal cultures, stimulations, and assessment of nuclear morphology.
Cortical neurons from embryonic day 21 Sprague Dawley rats were cul-
tured as described previously (Bading and Greenberg, 1991) except that
growth medium was comprised of Neurobasal A medium with B27 (In-
vitrogen), 1% rat serum, and 1 mM glutamine. Experiments were per-
formed after a culture period of 9–10 d, duringwhich neurons developed
a rich network of processes, expressed functional NMDA-type and
AMPA/kainate-type glutamate receptors, and formed synaptic contacts
(Hardingham et al., 2001a, 2002). Before stimulations, neurons were
transferred from growth medium to a medium containing 10% MEM
(Invitrogen), 90% salt-glucose-glycine (SGG) medium (Bading et al.,
1993) (114 mM NaCl, 0.219% NaHCO3, 5.292 mM KCl, 1 mM MgCl2, 2
mM CaCl2, 10 mMHEPES, 1 mM glycine, 30 mM glucose, 0.5 mM sodium
pyruvate, and 0.1%phenol red; osmolarity, 325mOsm/L).Neuronswere
treated with NMDA in the presence or absence of tetrodotoxin (TTX; 1
M; EMD Biosciences). To trigger NMDAR-dependent excitotoxic cell
death, neurons were exposed to NMDA or glutamate [in the presence of
nifedipine (5 M; Tocris Bioscience)] in our standard trophically de-
prived medium (90% SGG and 10%MEM) for 1 h, after which neurons
were washed once and returned to fresh medium. Neurons that die in
response to exposure to excitotoxic levels of glutamate exhibit swollen
cell bodies and pyknotic nuclei with small irregular chromatin clumps, a
characteristic of necrotic cell death as opposed to apoptotic-like death
(Fujikawa et al., 2000) [for example pictures, see Hardingham et al.
(2002)]. Cell death was determined 24 h later by counting the number of
4,6-diamidino-2-phenylindole (DAPI)-stained pyknotic/necrotic nu-
clei as a percentage of the total. For each treatment, 800–1000 cells were
scored across several random fields within three to four independent
experiments. When used, carbonyl cyanide p-trifluorometh-
oxyphenylhydrazone (FCCP) (1 M) and oligomycin (10 mM) were
added 5 min before stimulation. TAT-based peptides were used at 2 mM
and were added 1 h before stimulation, as were all pharmacological in-
hibitors. 10-(6-Ubiquinonyl) decyltriphenylphosphonium bromide
(MitoQ) and its decyltriphenylphosphonium bromide (DTPP) targeting
moiety control (gifts from Dr. Mike Murphy, University of Cambridge,
Cambridge, UK) were used at 5 M and added 1 h before stimulation.
Transfection and luciferase assays. AtT20 cells (European Collection of
Cell Cultures number 87021902) were maintained in DMEM medium
(Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen)
and antibiotics. AtT20 cells were transiently transfected in 24-well plates
with pCis vectors containing full-length mouse cDNAs encoding for the
NR1-1a (hereafter referred to as NR1) and NR2B subunits, along with a
SV40-luciferase plasmid in a 2:2:1 ratio, respectively. Transfection was
done using a total of 0.5 g of cDNA per well and 2.33 l/well of Lipo-
fectamine reagent (2g/ml) or Lipofectamine 2000 (1g/ml; both from
Invitrogen). Transfection was achieved following the manufacturer’s in-
structions and using the OptiMEM Imedium (Invitrogen). Transfection
efficiency was 5–10%. At the end of the transfection period, the mix-
ture was replaced with fresh OptiMEM I containing 50 M D-APV (Toc-
ris Bioscience) to prevent spontaneous NMDAR-induced cell death. As-
says were performed 16–24 h after the end of transfection. Transfected
AtT20 cells were stimulated with various glutamate concentrations for
5–7 h, with drugs being preapplied for at least 1 h before agonist appli-
cation. After the incubation period, themediumwas removed, and 90l
of Steady-Glo Luciferase Assay Kit (Promega) mixture was added to an
equal amount of fresh medium. Cells were allowed to lyse at room tem-
perature for 10 min and then transferred to opaque white 96-well plates
(Greiner Bio-One). Luciferase activity was measured by assaying the
chemiluminescence using FLUOstar Optima plate reader (BMG
Labtech). The relative light units were converted to percentage of cell
death compared with control (100%), and the minimum luminescence
value was normalized to 0% to account for transfection efficiency
variations.
To confirm the existence of functional NMDARs in the transfected
AtT20 cells, recordings of agonist-evoked whole-cell currents in
NMDAR-expressing AtT20 cells were made 18–72 h after transfection
using a Mg2-free external solution. Agonists (100 M glutamate and
100 M glycine) were applied with an independent line positioned near
the whole-cell clamped cell to achieve quick stimulation and tominimize
exposure of adjacent cells to agonists. Data were filtered at 1 kHz and
digitized at 5 kHz for subsequent off-line analysis.
Neurons were transfected at day in vitro 8 (DIV8) using Lipofectamine
2000 as described previously (McKenzie et al., 2005). Transfection effi-
ciency was2–5%. More than 99% of enhanced green fluorescent pro-
tein (eGFP)-expressing transfected neurons were NeuN positive, and
1%were GFAP positive (Papadia et al., 2008), confirming their neuro-
nal identity. For CRE-reporter assays, neurons were treated with bicu-
culline 24 h after transfection with 0.5 g of CRE-Luc plus 0.1 g of
pTK-Renilla. Bicuculline-induced activity was terminated [by ()-5-
methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine mal-
eate (MK-801) and TTX] after 30 min or 1 h, and luciferase expression
was analyzed 6–7 h later. Luciferase assays were performed using the
Dual-Glo assay kit (Promega) with firefly luciferase-based CRE-reporter
gene activity normalized to the Renilla control in all cases.
45Calcium assay: measurement of total, cytoplasmic, and vesicular Ca2
loads.Nifedipine (5 M) was added 1 h before the experiment to prevent
calcium entry through voltage-gated calcium channels. Cortical neurons
and NMDAR-expressing AtT20 cells were then stimulated for 10 min at
37°C with glutamate, using medium enriched with 30–50 MBq/L
45Ca2. After the 10 min incubation, cells were washed once with fresh
medium supplemented with kynurenate (10 mM) and magnesium (10
mM). For measuring total Ca2 load, cells were simply lysed with PBS
containing 1% Triton and transferred to scintillation vials. To measure
cytoplasmic and vesicular Ca2 load separately, we followed an estab-
lished procedure (Ward et al., 2005). Briefly, cytoplasmic Ca2 was re-
leased from the cells by adding 100 l of Ca2-free medium containing
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0.01% digitonin for 2 min, then collected for counting. The remaining
vesicular Ca2was thenmeasured by adding PBS/Triton as before. After
addition of 1 ml of scintillation liquid (VWR), Ca2 entry in counts per
minute was quantified using a Beckman LS6500 scintillation counter.
Data from each experiment were normalized for the amount of 45Ca2
activity used, and the basal radioactivity count from the nonstimulated
cells was subtracted from each subsequent condition.
Recordings and analysis of miniature EPSC and spontaneous EPSC fre-
quency. For miniature EPSC (mEPSC) recordings, neurons were placed
in medium containing control solution with or without 50 M bicucul-
line (Tocris Bioscience) for 15min and then returned to controlmedium
for 30 min. Coverslips were then transferred into a recording chamber
containing artificial CSF (aCSF) made of the following (in mM): 150
NaCl, 2.8 KCl, 10 HEPES, 2 CaCl2, 1 MgCl2, and 10 glucose, pH 7.3
(320–330mOsm). Patch pipettes were made from thick-walled borosili-
cate glass (Harvard Apparatus) and filled with a K-gluconate-based in-
ternal solution containing the following (in mM): 155 K-gluconate, 2
MgCl2, 10 Na-HEPES, 10 Na-Pi/creatine, 2Mg2-ATP, and 0.3 Na3-GTP,
pH 7.3 (300mOsm). These electrodes were coated with Sylgard 184 resin
(Dow Corning), and their tips were fire polished for a final resistance
between 5 and 10 M.
mEPSCs were recorded (Baxter and Wyllie, 2006) using an
Axopatch-1C amplifier (Molecular Devices) at room temperature (21
2°C) with the aCSF supplemented with 300 nM TTX and 50 M picro-
toxin (both from Tocris Bioscience). Events were recorded for 5–10 min
(minimumof 300 events) fromneurons clamped at70mV.Recordings
were rejected if the cell holding current was higher than 100 pA or if
series resistances drifted by 20% of their initial value and were 35
M. For data analysis, the tape-recorded mEPSCs were filtered at 2 kHz
and digitized at 10 kHz usingWinEDRversion 6.1 software (JohnDemp-
ster, University of Strathclyde, Glasgow, UK). Files were then analyzed as
described previously (Baxter and Wyllie, 2006) with MiniAnalysis soft-
ware (Synaptosoft). mEPSCs were manually selected with a minimum
amplitude threshold of 6 pA (approximately two times the baseline noise
level) and a maximum peak rising-time threshold of 5 ms.
Recordings of spontaneous EPSCs (sEPSCs) were obtained using an
aCSF with 3 mM CaCl2 to obtain a reliably high level of spontaneous
events in the cultures. Activity was recorded for 3 min while holding the
neuron at 70 mV. Only sEPSCs 200 pA and spaced by 1 s were
selected for frequency analysis.
Western blotting and antibodies. Total cell lysates were boiled at 100°C
for 5 min in 1.5	 sample buffer (1.5 M Tris, pH 6.8, 15% glycerol, 3%
SDS, 7.5% -mercaptoethanol, and 0.0375% bromophenol blue). Gel
electrophoresis and Western blotting were performed using the Xcell
Surelock system (Invitrogen)with precast gradient gels (4–20%) accord-
ing to the manufacturer’s instructions. The gels were blotted onto poly-
vinylidene difluoride membranes, which were blocked for 1 h at room
temperature with 5% (w/v) nonfat dried milk in TBS with 0.1% Tween
20. The membranes were incubated at 4°C overnight with the primary
antibodies diluted in blocking solution: anti-phospho-Jun Ser73 (1:500;
Cell Signaling Technology), phospho-Jun Ser63 (1:500; Cell Signaling
Technology), Jun (1:1000; BD Transduction Laboratories), phospho-
p38 Thr180/Tyr182 (1:400; Cell Signaling Technology), p38 (1:1000;
Santa Cruz Biotechnology) -tubulin isotype III (1:125,000; Sigma),
phospho-Akt Ser473 (1:500; Cell Signaling Technology), Akt (1:500; Cell
Signaling Technology), p-ASK1 Thr845 (1:1000; Cell Signaling Technol-
ogy), p-MKK4 Thr261 (1:1000; Cell Signaling Technology), hemagglu-
tinin (HA) (1:1000; Cell Signaling Technology), p-p44/42 MAPK
Thr202/Tyr204 (p-ERK1/2; 1:2000; Cell Signaling Technology), PSD-95
[1:1000; Abcam (goat)], and nNOS [1:500; Abcam (goat)]. For visualiza-
tion of Western blots, HRP-based secondary antibodies were used fol-
lowed by chemiluminescent detection on Kodak X-Omat film. Western
blots were analyzed by digitally scanning the blots, followed by densito-
metric analysis (ImageJ). All analysis involved normalizing to a loading
control, either to the unmodified version of themodificationunder study
(e.g., phospho-p38 normalized to p38) or to -tubulin isotype III.
RNA isolation, reverse transcription-PCR, and quantitative PCR. RNA
was isolated using the Qiagen RNeasy isolation reagents (including the
optional DNase treatment) after passage of the cells through a QiaShred-
der column. For quantitative PCR (qPCR), cDNA was synthesized from
1–3 g of RNA using the Stratascript QPCR cDNA Synthesis kit (Strat-
agene) according to themanufacturer’s instructions. Briefly, the required
amount of RNA (up to 3g) was diluted in RNase-free water (up to 7l
final volume) andmixed on ice with 1	 cDNA Synthesis master mix (10
l), random primers:oligo-dT primers (3:1) [total, 2 l (200 ng)], and
either 1 l of reverse transcriptase/RNase block enzyme mixture [for
reverse transcription (RT) reactions] or 1l of water (for no-RT control
reactions). Reactionmixtures weremixed and spun down and incubated
for 2min at 25°C, 40min at 42°C, and 5min at 95°C. cDNAwas stored at
20°C. Dilutions of this cDNA were used subsequently for real-time
PCR [cDNAequivalent to 6 ng of initial RNAper 15l qPCR for all genes
except glyceraldehyde-3-phosphate dehydrogenase (GAPDH); cDNA
equivalent to 2 ng of initial RNA per 15 l reaction for GAPDH]. qPCR
was performed in anMx3000PQPCRSystem (Stratagene) using Brilliant
SYBR Green QPCR Master Mix (Stratagene) according to the manufac-
turer’s instructions. Briefly, the required amount of template was mixed
on ice with 1	 Brilliant SYBR Green Master Mix, the required concen-
tration of forward and reverse primers, 30 nMROXpassive reference dye,
and water to the required reaction volume. Technical replicates as well as
no-template and no-RT negative controls were included, and at least
three biological replicates were studied in each case. The sequence and
concentration of the primers used are as follows: rat Adcyap1, forward
(F), 5-ATGTGTAGCGGAGCAAGG-3 (200 nM); reverse (R), 5-
GAGTGGCGTTTGGTAAGG-3 (200 nM); rat GAPDH, F, 5-AGAA-
GGCTGGGGCTCACC-3 (200 nM); R, 5-AGTTGGTGGTGCA-
GGATGC-3 (100 nM). The cycling program was 10 min at 95°C; 40
cycles of 30 s at 95°C, 40 s at 60°Cwith detection of fluorescence, and 30 s
at 72°C; and 1 cycle (for dissociation curve) of 1 min at 95°C and 30 s at
55°Cwith a ramp up to 30 s at 95°C (ramp rate, 0.2°C/s) with continuous
detection of fluorescence on the 55–95°C ramp. The data were analyzed
using theMxPro QPCR analysis software (Stratagene). Expression of the
gene of interest was normalized to GAPDH, a commonly used control.
Immunoprecipitation. For each treatment, 3	 35 mm dishes (1.5	
106 neurons) transfected with pHA-ASK1 or control (globin) expression
vector were lysed in 400 ml of lysis buffer [0.05 M Tris base, 0.9% NaCl,
pH 7.6, and 0.5% Triton X-100 plus Protease Inhibitors Cocktail Set III
(1:100; EMD Biosciences) and phosphatase inhibitor cocktails 1 and 2
(1:500; Sigma)]. Lysate was clarified at 16,000	 g for 15 min at 4°C. The
supernatant was then precleared with 25 ml of 50% Protein A Sepharose
(Sigma) for 1 h at 4°C, and after a brief spin, the pellet was discarded. Ten
percent of the supernatant was retained as input for normalization pur-
poses. The remainder was incubated overnight with 1:100 dilution of
anti-HA antibody (Cell Signaling Technology) at 4°C. The immunocom-
plex was precipitated with 25 ml of 50% Protein A Sepharose for 1 h at
4°C. The pellet was washed three times in lysis buffer, then boiled for 10
min in 25 ml of 1.5	 sample loading buffer (1.5 M Tris, pH 6.8, 15%
glycerol, 3% SDS, 7.5% -mercaptoethanol, and 0.0375% bromophenol
blue) before gel electrophoresis and Western blotting.
Neonatal focal ischemia models.All animal procedures were in compli-
ance with the directives of the Swiss Academy of Medical Science and
were authorized by the veterinary office of the Canton of Vaud. D-JNKI1
and Tat-NR2B9c peptides were dissolved in saline and administered in-
traperitoneally. Because the therapeutic time window with D-JNKI1 has
been shown to be 12 h,withmaximal protection at 6 h formiddle cerebral
artery occlusion (MCAO) in postnatal day 14 (P14) rats, we administered
D-JNKI1 at 6 h after the onset of ischemia; the chosen dose was 0.3mg/kg
(i.p.) because pilot experiments showed this to be optimal (A. Vaslin,
unpublished work). In contrast, Tat-NR2B9c (7.5 mg/kg) was given 30
min before cerebral ischemia, because the therapeutic window was un-
known. Control animals received saline. Focal ischemia was induced in
12-d-old male Sprague Dawley rats. Anesthesia was induced with 2.5%
isoflurane in a chamber and maintained during the operation with a
mask using 2.5% isoflurane. MCAO was performed as described previ-
ously (Borsello et al., 2003). A more severe model (MCAO) was per-
formed (Renolleau et al., 1998). Briefly, themain (cortical) branch of the
left middle cerebral artery was electrocoagulated just below the bifurca-
tion of the MCA into frontal and parietal branches (as per the MCAO
model). The left common carotid artery was then occluded by means of
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a clip for 90min, duringwhich time the rat pupsweremaintained at 37°C
in the induction chamber (2.5% isoflurane). The arterial clip was then
removed, and the restoration of carotid blood flow was verified under a
dissecting microscope before the skin incision was closed. Rat pups were
transferred back to their mothers for a 24 h survival period. This severe
model was compared with a milder model of permanent MCAO alone.
With both models, the survival rate until the rats were killed was 100%.
The volume of the infarct was measured after 24 h of recirculation.
Pups were heavily anesthetized with sodium pentobarbital and perfused
through the ascending aorta with 4% paraformaldehyde in PBS, pH 7.4.
Brains were removed, placed in PBS with 30% sucrose for15 h at 4°C,
and then frozen in isopentane (40°C). Cryostat coronal sections of 50
mwere stainedwith cresyl violet. The outline of the infarctwas traced in
each 10th slice using a computer-microscope system equipped with the
Neurolucida program (MicroBrightField), and the infarct volume was
calculated with NeuroExplorer (MicroBrightField). Lesions of5 mm3
(i.e., 10% of the mean lesion volume in saline controls) were consid-
ered artifactual (caused by technical error or vascular abnormality) and
were eliminated from the main analysis. Three saline control rats were
eliminated; however, reanalysis of the data confirmed that their inclusion
would have changed none of the conclusions.
Three pial vessel occlusion model of ischemia.Male Sprague Dawley rats
(n
 8 in each group) weighing between 280 and 320 g were used for this
study. Except for 12 h immediately preceding surgery, all animals had ad
libitum access to standard laboratory food before and after surgery. Ex-
perimental procedures were followed using guidelines established by the
Canadian Council for Animal Care and have been approved by the Uni-
versity Health Network Animal Care Committee. Rats were anesthetized
with a 0.5 ml/kg intramuscular injection of ketamine (100 mg/kg),
acepromazine (2 mg/kg), and xylazine (5 mg/kg), supplemented with
one-third of the initial dose as required. An anal temperature probe was
inserted, and the animal was placed on a heating padmaintained at 37°C.
The right external carotid artery (ECA) was cannulated with PE 10 poly-
ethylene tubing for dye injections. The skull was exposed via a midline
incision and scraped free of tissue, and the temporalis muscle was dis-
connected from the skull on the right side. Using a dissectingmicroscope
and a pneumatic dental drill, a 6	 4mm cranial window was made over
the right somatosensory cortex (2 mm caudal and 5 mm lateral to
bregma) by drilling a rectangle through the skull and lifting off the piece
of skull while keeping the dura intact. The tail vein was cannulated, and
drugs were injected in the following order: Tat-NR2B9c peptide (7.5
mg/kg) or saline, 15 min before ischemia; p38 inhibitor 4-(4-fluoro-
phenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole (SB202190)
(30 mg/kg) or saline 10 min before ischemia. After being bathed with
aCSF (maintained at 37°C), small boluses (10–20 l) of the vital dye
patent blue violet (10mmol/L; Sigma) in normal salinewere injected into
the right external carotid artery to demonstrate transit through surface
vessels of the cortex. Three critical arteriolar branches of the MCA
around the barrel cortexwere selected and electrically cauterized through
the dura. After the cauterizations, the bolus injections and dye transits
were repeated to ensure that transits through the cauterized arterioles
were blocked. The rectangle of skull was replaced over the window, and
the scalp was sutured. The catheter was removed from the ECA, the ECA
was ligated, and the anterior neck was sutured. Each rat was returned to
its individual cage under a heating lamp to maintain body temperature
until the rat fully recovered. Food and water was supplied ad libitum.
Twenty-four hours after surgery, animals were reanesthetized with 1 ml
of pentobarbital, and the brain was quickly harvested. Coronal slices (2
mm) was taken through the brain and incubated in 2% triphenyltetra-
zoliumchloride for 15min at 37°C. Imageswere scanned, and brain slices
were stored at80°C.
Results
The NR2 PDZ ligand is not needed for NMDAR-mediated
death in NMDAR-expressing AtT20 cells
We investigated cell death induced byNMDARs in the absence of
the neuron-specific NMDAR signaling complex by expressing
NR1/NR2B NMDARs in AtT20 cells (NR-AtT20 cells). The ulti-
mate aim of these experiments is to determine how the NMDAR
can signal to cell death in the absence of the neuronal NSC. Such
signals are likely to be activated in neurons, in addition to signals
that do require theNSC.Knowledge of both types of death signals
may help in developing an effective anti-excitotoxic strategy.
NR2B-containing NMDARs were chosen because the neurons
used in this study for comparison are DIV9 cortical neurons
whose NMDAR currents are NR2B dominated: whole-cell
NMDAR currents are inhibited by 68 6%by theNR2B-specific
antagonist ifenprodil (n
 6; data not shown). Pure NR1/NR2B
NMDARs are inhibited by80%by ifenprodil (Tovar andWest-
brook, 1999), indicating that the majority of NMDARs in DIV9
cortical neurons are NR2B containing. Consistent with this, ifen-
prodil prevents NMDAR-dependent neuronal cell death (see
below).
NR-AtT20 cells were subjected to patch-clamp analysis to
confirm the formation of functional NMDARs (Fig. 1A). For
viability studies, NR-AtT20 cells were cotransfected with a con-
stitutively active luciferase vector (pSV40-Luc), which acts as a
bioassay of NMDAR-dependent death in reconstituted systems
(Boeckman and Aizenman, 1996) in which transfection effi-
ciency is low (10% in AtT20 cells). Because of a more positive
resting membrane potential than neurons, spontaneous
NMDAR activity can be high in NMDAR-expressing non-
neuronal cells, so AtT20 cells were cultured after transfection in
50 M APV. Glutamate treatment caused death of NR-AtT20
cells in a dose-dependentmanner by outcompeting the APV (Fig.
1B), and was associated with Ca2 influx (measured using a
45Ca2 tracer) (Fig. 1C). Death/loss of luciferase signal was
blocked byMK-801 (Fig. 1B), and expression ofNR2B alone (i.e.,
no NR1) failed to confer glutamate-induced death on AtT20 cells
(Fig. 1B), confirming the need for functional NMDARs. To con-
firm that loss of luciferase signal corresponded to death, we cor-
roborated these findings by studying the glutamate-dependent
loss of eGFP-expressing NR-AtT20 cells (data not shown). To
further test the validity of the technique, we first confirmed that
in neurons, ifenprodil protected against glutamate-induced nu-
clear pyknosis (Fig. 1D) as well as preventing glutamate-induced
loss of luciferase signal fromneurons transfectedwith pSV40-Luc
(Fig. 1D).
We next studied the expression of PSD-95 and nNOS in
AtT20 cells, because these PDZ proteins are important in cou-
pling the NMDAR to cell death in neurons, via the NR2 PDZ
ligand (Cui et al., 2007).Western blot analysis revealed that levels
of PSD-95 and nNOS were extremely low in AtT20 cells, com-
pared with levels in equivalent amounts of neuronal protein ex-
tract (Fig. 1E). This suggests that the PDZ ligand of NR2B may
not be important for NMDAR-dependent cell death in NR-
AtT20 cells. To test this, AtT20 cells were transfected with vectors
encoding NR1 plus a truncated form of NR2B lacking the PDZ
ligand, NR2Btrunc (Rutter and Stephenson, 2000). Expression of
NMDARs containing NR1 and NR2Btrunc triggered the same
Ca2 load (Fig. 1F) and also was as effective at promoting cell
death (Fig. 1G) as expression of wild-type (WT)NMDARs. Thus,
in the non-neuronal environment of anAtT20 cell, NMDARs can
couple to cell death in the absence of PSD-95, nNOS, and the
NR2B PDZ ligand, all components that contribute to NMDAR
excitotoxicity in neurons (Cui et al., 2007).
Differing p38MAPK dependency of NMDAR signaling to
death in neurons versus NR-AtT20 cells
To investigate this apparent paradox, we studied the signals re-
sponsible for mediating NMDAR-dependent cell death in neu-
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rons and NR-AtT20 cells, focusing on two key mediators of exci-
totoxicity, the SAPKs p38 and JNK (Kawasaki et al., 1997;
Borsello et al., 2003). Under basal conditions, CNS neurons con-
tain a pool of active JNK1, which does not influence viability, but
can make it difficult to detect additional elevation of stress-
activated JNK signaling with phospho-JNK antibodies (Coffey et
al., 2002). Because this pool of JNK1 does not influence c-Jun
phosphorylation, the latter was used as a sensitive metric of
NMDAR-dependent JNK signaling (Fig. 2A). NMDAR-
dependent c-Jun phosphorylation was inhibited by the JNK in-
hibitor 1,9-pyrazoloanthrone (SP600125), as well as the peptide
inhibitor of JNK, D-JNKI1 (Borsello et al., 2003) (Fig. 2A), but
not the p38 inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfonyl-
phenyl)-5-(4-pyridyl)-1H-imidazole (SB203580) (data not
shown). SP600125 did not interfere with p38 autophosphoryla-
tion, in contrast to SB203580 (data not shown). In neurons,
NMDAR activation induced both p38 and JNK signaling (Fig.
2B,C). Because we did not have access to neurons from JNK
and p38 isoform-deficient mice, we tested the JNK/p38 inhib-
itors on NMDA-induced excitotoxicity to see whether these
stress-activated protein kinases play a role in excitotoxicity in
our system. Inhibitors of JNK and p38 reduced NMDAR-
dependent cell death (Fig. 2D), indicating a contribution from
both pathways.
In contrast to the effects of both JNK and p38 inhibitors on
NMDAR-dependent neuronal death, JNK inhibition completely
blocked NMDAR-dependent death of NR-AtT20 cells, whereas
p38 inhibition had no effect (Fig. 2E). This is not because of
absence of the p38 pathway in AtT20 cells: known SAPK activa-
tors, H2O2 and anisomycin, induced p38 activation (data not
shown). The absence of a p38-dependent component of
NMDAR-dependent death of NR-AtT20 cells indicated that
neuron-specific signaling molecules may be required for p38 ac-
tivation by NR2B-containing NMDARs.
Figure 1. NMDAR-mediated Ca 2 influx can kill NMDAR-expressing AtT20 cells in the absence of PSD-95, nNOS, or the NR2 PDZ ligand.A, AtT20 cells transfectedwith pNR1 and pNR2B plasmids
express functional NMDARs. An example trace of agonist (100M glutamate; horizontal bar)-induced current in NMDAR-expressing AtT20 cells (NR-AtT20) is shown. B, Reconstituting NMDAR-
dependent cell death inAtT20 cells. NR-AtT20 cellswere treatedwithglutamate (Glu) for 5–7h. Cellswere cotransfectedwithpSV40-Luc toenable viability tobemeasuredbyperforminga luciferase
assay on lysates. Mean SEM are shown in this and all subsequent figures (n
 7). C, Measuring Ca 2 influx in NR-AtT20 cells. NR-AtT20 cells were incubated in 45Ca 2-containingmedium and
treatedwithglutamate for 10min (n
3).D, NR2B-containingNMDARsmediate excitotoxicity inDIV9 cortical neurons.Neuronswere treatedas indicatedwithglutamatewithorwithout ifenprodil
(Ifen; 3M). Neuronswere transfectedwith pSV40-Luc to enable viability to bemeasured by a luciferase assay. In parallel, cell deathwasmeasured by counting pyknotic and nonpyknotic nuclei (n

 3). Bottom, Example pictures. Con, Control; Veh., vehicle. E, Western analysis of nNOS and PSD-95 expression in equal quantities of protein extracts (by BCA assay) from AtT20 cells and cortical
neurons. Calmodulin expression is also shown for comparison.F, NMDARs containinga truncatedNR2B (lacking theC-terminal 4 aa)mediate the sameglutamate-dependent Ca 2 load aswild-type
NR2B-containingNMDARs. AtT20 cellswere transfectedwith pNR1 and eitherWTNR2BorNR2Btrunc. Twenty-four hours later, cellswere incubated in 45Ca 2-containingmediumand treatedwith
glutamate for 10min (n
 3).G, NMDARs containingNR2Btrunc are as effective at promoting glutamate-dependent cell death aswild-typeNR2B-containingNMDARs. AtT20 cellswere transfected
with pNR1 and either WT NR2B or NR2Btrunc, plus pSV40-Luc. Twenty-four hours after transfection, cells were treated with glutamate for 5–7 h before luciferase assay (n
 3).
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NMDAR signaling to p38MAPK involves NOS and requires
only submembranous Ca2 in neurons
In cortical neurons, p38 is an important downstream effector of
NO toxicity (Ghatan et al., 2000), and in cerebellar granule cells
NMDAR-dependent p38 activation is NOS-dependent (Cao et
al., 2005). To determine whether NMDAR signaling to p38 is
NOS-dependent in cortical neurons, we treated them with the
NOS inhibitors L-N-nitroarginine methyl ester (L-NAME) and
7-nitroindazole (in arginine-free medium). Both inhibitors im-
paired p38 activation by NMDA (Fig. 3A) but not by H2O2 treat-
ment (data not shown), indicating that NOS activation by
NMDA is upstream of p38 in cortical neurons. To determine
whether NO was sufficient to induce p38 activation in cortical
neurons, we exposed them to the NO donor S-nitroso-N-
acetylpenicillamine (SNAP), and found efficient p38 activation
(Fig. 3B) that was transient, as is NMDAR-induced p38 activa-
tion (data not shown). The transient nature of p38 activation
[phosphorylation followed by dephosphorylation (data not
shown)] has been observed previously (Waxman and Lynch,
2005). The ability of NMDARs (specifically NR2B-containing
NMDARs) to trigger p38 dephosphorylation (Krapivinsky et al.,
2004; Waxman and Lynch, 2005) raises the question of whether
NOS inhibitors act by blocking NMDAR-dependent p38 activa-
tion, or by slowing the p38 desphosphorylation. The former is
more likely: even at 1min stimulation, which is before full induc-
tion of p38, L-NAME inhibitsNMDAR-dependent p38 activation
(data not shown).
Whereas some NMDAR-dependent events, such as
calcineurin-dependent NFAT (nuclear factor of activated
T-cells) translocation, require bulk cytoplasmic Ca2 increases,
others, such as the Ras-ERK1/2 pathway, require only submem-
branous Ca2 increases in the immediate vicinity of theNMDAR
(Hardingham et al., 2001b). A sole requirement for submembra-
nous Ca2 would indicate receptor-proximal effectors of the
NOS-p38MAPK cascade. To determine this, we used a technique
we previously established involving the cell-permeable Ca2 che-
lator EGTA-AM and bicuculline (Hardingham et al., 2001b).
Brief, easily bufferable, NMDAR-dependent Ca2 transients
were generated by network disinhibition using GABAA receptor
blockade (bicuculline). These transients activated p38 in a MK-
801-sensitivemanner, just likeNMDAbath application (Fig. 3C).
We previously showed that preloading EGTA-AM at increasing
concentrations before bicuculline stimulation blunts global Ca2
transients at low doses of EGTA-AM, and abolishes them at 100
MEGTA-AM(Hardinghamet al., 2001b). The bicuculline stim-
ulation is needed rather than bath NMDA, because the latter
saturates the EGTA buffer. Because EGTA has a slow on-rate for
Ca2 binding, it allows increases in Ca2 very near the site of
entry, so bicuculline-induced bursting, reliant on evoked neuro-
transmitter release (a classical membrane-proximal Ca2-
dependent process), still takes place (Hardingham et al., 2001b).
Thus, EGTA-AM restricts intracellular Ca2 transients to the
immediate vicinity of the site of entry (the NMDAR). Strikingly,
EGTA-AM loading did not compromise the activation of p38
after bicuculline treatment, even at 100 M (Fig. 3D,E). In con-
trast, activation of Akt, another known NMDAR-activated sig-
nalingmolecule, is abolished (Fig. 3D,F).We confirmed that p38
activation by bicuculline stimulation is NMDAR dependent (Fig.
3C), and NMDAR-dependent activation of p38 requires Ca2
influx (no activation was observed in Ca2-free medium; data
not shown). We conclude from Figure 3 that Ca2 elevation in
the immediate vicinity of the NMDAR is sufficient to trigger
NOS-dependent p38 signaling in cortical neurons.
NMDAR signaling to p38MAPK in neurons is disrupted by a
peptide mimetic of the NR2B PDZ ligand
A recent study in cerebellar granule neurons showed that uncou-
pling of the NMDAR-associated scaffold protein PSD-95 from
associated proteins, including nNOS (by overexpressing their in-
teraction domains), impaired signaling to p38 (Cao et al., 2005).
PSD-95 associates with the NMDAR via the C-terminal PDZ
ligand of NR2. To determine whether the NR2 PDZ ligand plays
a role in the NOS-dependent activation of p38 signaling in corti-
cal neurons, we treated neuronswith TAT-NR2B9c, a cell perme-
able (TAT-fused) peptide mimetic of the 9 C-terminal amino
acids of NR2B, containing the PDZ ligand. TAT-NR2B9c dis-
rupts NR2B/PSD-95 interactions, and uncouples the NMDAR
from NO production (Aarts et al., 2002). TAT-NR2B9c strongly
Figure 2. Differing p38MAPK dependency of NMDAR pro-death signaling in neurons versus
NR-AtT20 cells. A, NMDAR-dependent c-Jun phosphorylation is JNK dependent. Cortical neu-
rons were treated with the JNK inhibitors SP600125 (3M) and D-JNKI (2M) for 1 h before
stimulation with NMDA (20M) for 30 min (n
 3). *p 0.05, two-tailed Student’s t test in
this and all subsequent figures unless otherwise indicated. Western analysis of phospho-Jun
(Ser73) levelswas normalized to c-Jun levels (n
3).B,Western analysis of the dose–response
of JNK-dependent Jun phosphorylation with NMDA stimulation in cortical neurons (n
 5). C,
Western analysis of the dose–response of p38 phosphorylation with NMDA stimulation in cor-
tical neurons (n
5).D, NMDAR-mediatedneuronal cell death ismediatedbyboth JNKandp38
signaling. Neurons were treated with inhibitors of p38 (SB203580, 5M; SB202190, 5M) or
JNK (SP600125, 1M) for 1 h before a 1 h excitotoxic insult. Neuronal loss was assessed after
24 h (n
 3). Con, Control. E, NMDAR-dependent death of NR-AtT20 cells is totally JNK depen-
dent. NR-AtT20 cells were treated with inhibitors of p38 (SB203580) or JNK (SP600125) for 1 h
before glutamate treatment at the indicated concentrations. Luciferase assay was performed
5–7 h later. *p 0.05, significant protection compared with control (n
 3).
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impaired NMDAR-dependent p38 activa-
tion (Fig. 4A), without impairing
NMDAR-dependent Ca2 influx as as-
sayed by 45Ca2 accumulation (supple-
mental Fig. S1, available at www.jneurosci.
org as supplemental material). TAT-
NR2B9c did not effect basal levels of p38
activity, nor did it effect p38 activation by a
different stimulus (H2O2 treatment; data
not shown). Thus, the effect of TAT-
NR2B9c on p38 signaling appears to be
specific to NMDAR-dependent p38
activation.
TAT-NR2B9c did not inhibit
NMDAR-dependent activation of JNK
signaling (Fig. 4B). Note that the effect of
TAT-NR2B9c on p38 activation was ob-
served at both the point of peak p38 activ-
ity (5 min) (Fig. 4A) and 30 min (data not
shown), the time point at which the lack of
JNK inhibition was observed.
Given that NMDAR-dependent death
of NR-AtT20 cells is JNK dependent (Fig.
2E) and does not rely on the NR2 PDZ
ligand (Fig. 1G), we would expect that
TAT-NR2B9cwould not impairNMDAR-
dependent cell death of NR-AtT20 cells.
This is indeed the case: TAT-NR2B9c had
no effect on NMDAR-dependent death of
NR-AtT20 cells (data not shown). Thus,
the effect of TAT-NR2B9c on NMDAR
signaling to cell death is specific to the p38
pathway, and further supports the idea
that JNK signaling is independent of the
NR2 PDZ ligand. Moreover, TAT-
NR2B9c also impaired activation of ASK1
(Fig. 4C), a known upstream activator of
p38 in neurons (Takeda et al., 2004) (as
measured by analyzing Thr-854 phos-
phorylation). Together, the data in Figures
3 and 4A–C support the hypothesis that
NMDAR-dependent activation of p38 can
be triggered by submembranous Ca2,
and requires the NR2 PDZ ligand to cou-
ple to associated proteins in cortical
neurons.
Consistent with previous studies, TAT-
NR2B9c reduced NMDAR-dependent
neuronal death as assayed by studying nu-
clear pyknosis (Fig. 4D; example phase-contract pictures also
shown). Using an alternative assay of cell viability, ATP levels,
TAT-NR2B9c also reduced NMDAR-dependent neuronal death
(Fig. 4E). We next investigated whether the neurons “protected”
by TAT-NR2B9cwere functional, focusing on the TAT-NR2B9c-
treated neurons that were exposed to an ordinarily toxic dose of
NMDA (40 M). In current-clamp recordings, we injected cur-
rent into the surviving cells (with 300 ms pulses at 1 Hz) to bring
them to threshold. In current-clamp configuration, all surviving
cells studied fired action potential bursts when depolarized be-
yond 40 mV, as was observed with non-NMDA-treated neu-
rons (Fig. 4F). In voltage clamp, we also measured sEPSC fre-
quency in surviving cells, to determine whether surviving
neurons remained synaptically connected to other neurons. The
prolonged nature of these sEPSCs presumably reflects the fact
that these events are associated with action-potential bursts of
activity that occur in the rest of the network of cultured neurons.
In neurons treated with 40 M NMDA alone, there was a severe
decrease in sEPSC frequency of surviving cells (Fig. 4G), consis-
tent with the large amount of cell death (each surviving neuron
would be connected to fewer neurons). In contrast, neurons that
are protected by TAT-NR2B9c after an excitotoxic insult exhibit
no such reduction in sEPSC frequency (Fig. 4G), indicating that
not only does TAT-NR2B9c prevent cell death, but that by this
assay, overall connectivity and excitability of the neurons are
preserved.
TAT-NR2B9c reduces focal ischemic brain damage in rats
(Aarts et al., 2002), and the results above suggest that this may be
Figure 3. NMDAR signaling to p38 MAPK in cortical neurons involves NOS and requires only submembranous Ca 2. A,
NMDAR-dependent p38 activation in cortical neurons is NOS dependent. Neurons were placed in arginine-free medium and
treated with either vehicle or a NOS inhibitor for 1 h [L-NAME at 500M and 7-nitroindazole (7-NI) at 5M]. Neurons were then
stimulatedwithNMDA (20M) for 5minbefore harvesting andWestern analysis (n
4). Con, Control.B, Nitric oxidedonor SNAP
is sufficient to induce p38 activation in cortical neurons. Neuronswere treatedwith theNOdonor SNAP (500M) for the indicated
times before harvesting and Western analysis ( p 0.05 compared with untreated neurons; n
 3–4). C, Bicuculline-induced
synaptic activity promotes NMDAR-dependent p38 and Akt activation. Western analysis of p38 and Akt activation in cortical
neurons was performed using phosphospecific antibodies. Neurons were stimulated with NMDA (20M) or bicuculline (BiC; 50
M) for 5minwith or without MK-801 (10M).D–F, Eliminating global Ca 2 transient by loading neurons with EGTA-AM does
not affect p38 activation, but abolishes Akt activation. D, Western analysis of p38 and Akt activation in neurons stimulated with
bicuculline for 2 or 5min. Before bicuculline stimulation, neuronswere preloadedwith EGTA-AM at room temperature for 20min
(Hardingham et al., 2001b). E, Analysis of the effect of EGTA-AM on bicuculline-induced p38 activation (n
 3). F, Analysis of the
effect of EGTA-AM on bicuculline-induced Akt activation (n
 3).
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Figure4. NMDAR signaling to p38MAPK in neurons is disrupted by a peptidemimetic of theNR2B PDZ ligand.A, TAT-NR2B9c uncouples theNMDAR fromp38 activation.Western analysis of p38
activation was performed in cortical neurons stimulated with NMDA (20M) for 5 min (n
 6). All TAT-peptides were used in this study at 2M, and cells were pretreated for 1 h. B, TAT-NR2B9c
does not affect NMDAR-dependent JNK signaling.Western analysis of activation of JNK-dependent Junphosphorylationwas performed in cortical neurons stimulatedwithNMDA (20M) for 30min
after pretreatmentwith TAT-NR2B9c (for 1 h) as indicated (n
 3). C, TAT-NR2B9c uncouples the NMDAR fromASK1 activation. Neuronswere transfectedwith pHA-ASK1 and after 24 h stimulated
with NMDA (20 M) and pretreated with vehicle or TAT-NR2B9c (n 
 3). HA-ASK1 was immunoprecipitated and subject to Western analysis of activation (Figure legend continues.)
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via p38 inhibition. If this were the case, then the model of focal
ischemia amenable to protection by TAT-NR2B9c (Aarts et al.,
2002) should cause brain damage that is p38 dependent. We per-
formed the three pial vessel occlusion (3PVO) model of focal
ischemia on adult rats, which involves cauterization of three ter-
minal pial branches of the middle cerebral artery. Brain injury
after 3PVO is nearly completely protected by treatment with
TAT-NR2B9c (Fig. 4H, I). We then tested the effect of adminis-
tering the p38 inhibitor SB202190 and found that this too offered
very strong protection against brain damage after 3PVO (Fig.
4H, I; supplemental Fig. S2, available at www.jneurosci.org as
supplemental material), suggesting that TAT-NR2B9c and the
p38 inhibitor may be acting on a common pathway in vivo, as is
the case in vitro.
TAT-NR2B9c does not block survival or plasticity signaling,
unlike conventional NMDAR antagonists
An aim of this study is to determine whether the NMDAR can be
uncoupled from pro-death signaling without impairing prosur-
vival signaling, or synaptic plasticity. We first investigated the
effect of TAT-NR2B9c on PI3K–Akt signaling and activation of
cAMP response element-binding protein (CREB)-dependent
gene expression, key mediators of synaptic NMDAR-dependent
neuroprotection (Papadia et al., 2005; Hardingham, 2006). TAT-
NR2B9c did not impair activation of CREB-dependent reporter
activation triggered by an episode of synaptic NMDAR activity
lasting 1 h or 30 min (Fig. 5A and data not shown). In fact,
TAT-NR2B9c had a small but significant potentiating effect (Fig.
5A), the basis for which is not clear. Consistent with an absence of
a role for either p38 or JNK in activity-dependent CREB activa-
tion, neither SB203580 nor SP600125 impaired activation of the
CRE reporter (data not shown). TAT-NR2B9c also did not inter-
fere with activity-dependent induction of a CREB target gene
Adcyap1 (Fukuchi et al., 2005), which encodes the neuroprotec-
tive ligand PACAP (pituitary adenylate cyclase-activating
polypeptide; data not shown). TAT-NR2B9c had no effect on
synaptic NMDAR signaling to Akt activation triggered by an ep-
isode of synaptic NMDAR activity lasting 1 h or 30 min (Fig. 5B
and data not shown). The NMDAR antagonist MK-801 pro-
motes apoptotic-like neurodegeneration in trophically deprived
conditions (Papadia et al., 2005).However, TAT-NR2B9c did not
promote neuronal death, in contrast to MK-801 (Fig. 5C).
We next sought to determinewhether TAT-NR2B9c impaired
NMDAR-dependent synaptic plasticity. We used a neuronal cul-
ture model of plasticity (Arnold et al., 2005) in which a brief
period of bicuculline-induced bursting causes an NMDAR-
dependent increase in mEPSC frequency in hippocampal neu-
rons (for example traces, see Fig. 5D,E), attributed to AMPA
receptor insertion and unsilencing of synapses (Abegg et al.,
2004). We found that, whereas MK-801 blocked the increase in
mEPSC frequency, TAT-NR2B9c had no effect (Fig. 5D,E).
SP600125 did not suppress the synaptic NMDAR-dependent en-
hancement ofmEPSC frequency; however, SB203580 did have an
inhibitory effect (data not shown). Thus, TAT-NR2B9c has a
4
(Figure legend continued.) of ASK1, measured by analyzing ASK1 (Thr-845) phosphorylation.D,
TAT-NR2B9c protects neurons against NMDAR-dependent excitotoxic cell death. Neurons
treatedwith TAT-NR2B9cor control peptide for 1hbefore excitotoxic insult (NMDA) for 1h. Left,
Neuronal loss assessed after 24 h by DAPI staining and counting pyknotic nuclei (n
 3). Right,
Phase-contrast pictures illustrating the protective effects of TAT-NR2B9c. Scale bar, 50 m.
Note the phrase-bright cell debris fromdead neurons in the control cultures treatedwith 40M
NMDA (top right). E, TAT-NR2B9c protects neurons against NMDAR-dependent excitotoxic cell
deathas assayedby loss of cellularATP.Neuronswere treatedas inD, andafter 24h, cellularATP
levels were measured by CellTiter-Glo assay (Promega; n
 4). F, Neurons that are protected
from NMDA toxicity by TAT-NR2B9c pretreatment fire action potentials as normal. Neurons
were treated as indicatedusing the sameprotocol as inD. Twenty-four hours after 40MNMDA
exposure, surviving cells were patched under current clamp. Current was then injected (300ms
pulses at 1 Hz) until depolarized beyond40mV. Examples show the firing response that was
triggered. G, Neurons that are protected from NMDA toxicity by TAT-NR2B9c pretreatment
experience normal levels of synaptic activity. Neuronswere treated as indicated using the same
protocol as in D. Twenty-four hours after 40 M NMDA (or vehicle) exposure, surviving cells
were recorded under voltage clamp. sEPSC frequency of the neuronswas thenmeasured over 3
min of recording time (analysis shown on left, example traces on right).*p 0.05 compared
with control neurons (n
 7). H, TAT-NR2B9c and the p38 inhibitor SB202190 reduce infarct
size in the 3PVO model of stroke. Adult rats were treated with TAT-NR2B9c (7.5 mg/kg) or the
p38 inhibitor SB202190 (30mg/kg) intravenously via a tail vein cannula 15minbefore ischemia
(3PVO; see Materials and Methods). Animals were killed 24 h after ischemia, and coronal brain
sliceswere taken for analysis of infarct size (n
8 for eachgroup). Con, Control. I, Examplebrain
slices (analysis inH ) stained in 2% triphenyltetrazolium chloride; infarcts are highlighted with
white arrowheads.
Figure 5. TAT-NR2B9c does not block survival or plasticity signaling, unlike conventional
NMDAR antagonists. A, TAT-NR2B9c does not impair synaptic NMDAR-dependent activation of
a CRE reporter. Neurons were transfected with a CRE-firefly luciferase vector plus pTK-Renilla
transfection control. Twenty-four hours after transfection, neurons were pretreated with the
peptides (2M) orMK-801 (10M) for 1 h before bicuculline (BiC) stimulation for 1 h. After 1 h,
synaptic activity was terminated by TTX (1M) andMK-801 (10M), and luciferase expression
was measured after a further 6–7 h. CRE-firefly luciferase activity is normalized to Renilla
control (n
 3). B, TAT-NR2B9c does not impair synaptic NMDAR-dependent activation of Akt.
Shown is Western analysis of Akt activation by bicuculline treatment, and the effect of the
indicated peptides and drugs (n
 3). C, TAT-NR2B9c does not promote neuronal apoptosis,
unlike MK-801. Neurons were placed in trophically deprivedmedium and treated with vehicle,
MK-801, or TAT-NR2B9c for 72 h before fixation and DAPI staining. In the case of TAT-NR2B9c,
fresh peptide was added every 24 h. The number of DAPI-stained apoptotic-like nuclei as a
percentage of the total was calculated (n 
 4). D, TAT-NR2B9c does not block NMDAR-
dependent synaptic plasticity. Hippocampal neurons were pretreated for 1 h with peptide or
MK-801 as indicated and in the presence of these compounds were treated with mediumwith
or without bicuculline for 15 min and then allowed to settle for 30 min. mEPSCs were then
recorded for 5–10min (minimum300events), and the frequencywas calculated (n
8–10 for
each condition). Con, Control. E, Examples of traces used to generate the data shown in D.
unstim, Unstimulated.
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clear advantage over a global smallmolecule inhibitor of p38with
regard to unwanted interference with this plasticity model.
We also studied the effect of TAT-NR2B9c on basal activity
and found that mEPSC frequency was not altered by TAT-
NR2B9c, nor was sEPSC frequency affected (data not shown),
indicating that overall excitability of the neuronal network is not
altered. Thus, TAT-NR2B9c can impair NMDAR-dependent
pro-death signaling, without interfering appreciably with
NMDAR-dependent prosurvival signaling or a model of
NMDAR-dependent synaptic plasticity.
JNK activation by mitochondrial reactive oxygen species
The JNK dependency of NMDAR-mediated cell death of NR-
AtT20 cells revealed that this signaling cassette may not require
the NMDAR signaling complex. Consistent with this, TAT-
NR2B9c did not interfere with JNK activation (Fig. 4B). These
observations raise the possibility that the Ca2 effector of JNK
activationmay be away from the NMDA receptor signaling com-
plex at a different subcellular location. Ca2 uptake into mito-
chondria, through the potential-driven uniporter, is known to
play a role in NMDAR-dependent cell death (Stout et al., 1998)
and triggers the production of reactive oxygen species (ROSs)
(Nicholls, 2004), regulators of JNK signaling (Torres and For-
man, 2003). To investigate the role of mitochondrial ROS pro-
duction in JNK activation, we treated neurons with the mito-
chondrially targeted ubiquinone-based antioxidant, MitoQ
(Kelso et al., 2001). MitoQ strongly inhibited NMDA-induced
JNK signaling (Fig. 6A), but not p38 activation (Fig. 6B), whereas
the targeting moiety (DTPP) had no effect on JNK (Fig. 6A).
Recently, protein kinase D (PKD; also known as PKC) was
shown tomediate the activation of JNK signaling by ROS inHEK
cells (Eisenberg-Lerner and Kimchi, 2007). To investigate the
role of PKC/PKD inneurons, we used the establishedmethodof
applying PKC isoform inhibitors with slightly different specific-
ities (Lemonnier et al., 2004; Zhang et al., 2005; Ivison et al.,
2007): 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-
oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole (Go¨6976) inhib-
its multiple isoforms of PKC, including , , and  (PKD)
isoforms, whereas 2-[1-(3-dimethylaminopropyl)-5-methoxy-
indol-3-yl] -3-(1H- indol-3-yl)maleimide (Go¨6983) blocks
PKC, , , , and  isoforms, but not PKC/PKD. We found
that Go¨6976, but not Go¨6983, inhibited NMDAR-dependent
JNK signaling (supplemental Fig. S3, available at www.
jneurosci.org as supplemental material). Because PKC/PKD is
the only known kinase that is inhibited by Go¨6976 but not by
Go¨6983, this implicates PKC/PKD in the activation of JNK by
NMDAR-dependent mitochondrial ROS production. However,
we cannot rule out that any hitherto unknown kinases that are
blocked by Go¨6976 but not Go¨6983 could also be responsible for
the effects that we observe.
An implication of the inhibitory effect of MitoQ is that inter-
fering with mitochondrial Ca2 uptake may impair JNK signal-
ing. NMDAR activation induces a dose-dependent increase in
vesicular Ca2 load, the majority of which is mitochondrial
(Ward et al., 2005).Mitochondrial Ca2uptake can be prevented
by predepolarizing the mitochondria with the uncoupler FCCP,
which has been reported to reduce NMDAR-dependent cell
death (Stout et al., 1998).We treated neurons with FCCP plus the
mitochondrial ATPase inhibitor oligomycin (to prevent deple-
tion of cytoplasmic ATP through ATPase reversal). FCCP/oligo-
mycin (F/O) pretreatment dramatically reduced vesicular Ca2
uptake triggered by 20 M NMDA (Fig. 6C), confirming that
mostNMDA-induced vesicular Ca2 uptakewas intomitochon-
dria [the remainder being into the endoplasmic reticulum (Ward
et al., 2005)]. Consistent with a major uptake mechanism being
blocked, cytoplasmic Ca2 load triggered by 20 M NMDA was
increased by F/O pretreatment (Fig. 6D) to levels similar to those
Figure 6. JNK activation involves mitochondria. A, B, MitoQ blocks NMDAR-dependent JNK
signaling, but not p38 activation. Shown is Western analysis of NMDAR-mediated JNK-
dependent Jun phosphorylation (A) and p38 activation (B) in neurons pretreated for 1 h with
vehicle, MitoQ (5M), or DTPP control (5M) (n
 4). C, Predepolarization of mitochondria
blocks NMDA-induced vesicular Ca 2 uptake. Neurons were pretreated (for 5 min) where in-
dicated with F/O before stimulation andmeasurement of vesicular 45Ca 2 uptake (n
 3). D,
Predepolarization of mitochondria causes an increase in NMDA-induced cytoplasmic Ca 2
load. Neurons were pretreated where indicated with F/O before stimulation andmeasurement
of cytoplasmic 45Ca 2 uptake (n
 3). For reference, the level of cytoplasmic 45Ca 2 uptake
induced by 50 M NMDA is also shown. E–H, Predepolarization of mitochondria blocks JNK
signaling but not p38 or ERK1/2. Shown is an assessment of the effect of F/O pretreatment on
NMDA induction of c-Jun phosphorylation on serine-73 (E; example blot below) and c-Jun
phosphorylation on serine-63 (F; example blot above), both normalized to c-Jun levels (n
 3),
p38 activation (G; example blot below; n
 3), and ERK1/2 phosphorylation (H; example blot
above). Phosphorylation levels in G and H are normalized to p38.
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induced by 50 M NMDA in the absence of F/O. Indeed, F/O
pretreatment inhibited NMDA-induced JNK signaling (Fig.
6E,F), whereas NMDAR coupling to p38 and ERK1/2 activation
was not affected (Fig. 6G,H).
Effective anti-excitotoxic therapy by combining TAT-NR2B9c
with a TAT-fused JNK inhibitor in vitro and in vivo
Interestingly, we found that TAT-NR2B9c was not neuroprotec-
tive at high doses of NMDA (100M) (Fig. 7A). Given that TAT-
NR2B9c interferes with NMDAR pro-death signaling to p38 and
not JNK, we hypothesized that both pathwaysmust be blocked to
achieve protection after exposure to high doses of NMDA. We
tested the neuroprotective effect of TAT-NR2B9c in combination
with the cell-permeable peptide JNK inhibitor, D-JNKI1
(Borsello et al., 2003) (Fig. 2A). Although either peptide alone
was protective against moderate doses of NMDA, neither was
effective against 100 M NMDA. However, when combined they
offered significant neuroprotection at 100 M NMDA (Fig. 7A).
Thus, both SAPK pathways must be blocked to offer neuropro-
tection against a severe excitotoxic insult. Although both TAT-
NR2B9c andD-JNKI1 protect againstmodels of rodent focal isch-
emia (Aarts et al., 2002; Borsello et al., 2003), we hypothesized
that theymayworkwell in combination in vivo. Given the efficacy
of these peptides on their own, we sought a severe model of
ischemia beyond the protective effects of either peptide
individually.
D-JNKI1 alone gives strong protection against focal ischemia
caused by MCAO in neonatal rats or adult mice (Borsello et al.,
2003), so we created a stronger ischemic insult in P12 rats by
combiningMCAOwith 90min closure of the ipsilateral common
carotid artery (MCAO) (Renolleau et al., 1998). This produces
more complete ischemia, reducing irrigation of the ischemic
zone by anastomoses from the anterior and posterior cerebral
arteries. MCAO resulted in larger infarcts than MCAO (Fig.
7B). Furthermore, although D-JNKI1 alone given 6 h after the
onset of ischemia reduced the infarct volume in the MCAO
model (Fig. 7B,C), the same dose given either 30 min before or
6 h after the MCAO procedure was ineffective (Fig. 7D). The
effects of TAT-NR2B9c alone or in combination with D-JNKI1
were also tested. Because the therapeutic window for D-JNKI1 is
Figure 7. Effective anti-excitotoxic therapy by combining TAT-NR2B9cwith a TAT-fused JNK inhibitor in vitro and in vivo. A, TAT-NR2B9c and D-JNKI1 are additively anti-excitotoxic in neurons in
vitro. Cortical neurons were pretreated with the indicated peptides for 1 h before excitotoxic insult (NMDA) for 1 h. Neuronal loss was assessed after 24 h (n
 3). B, D-JNKI1 provides effective
treatment ofMCAO alone, and theMCAOmodel results in large infarcts. Saline or D-JNKI1 (0.3mg/kg, i.p.)was administered 6 h after simpleMCAO (*p 0.001, Student’s t test). For comparison,
infarct size caused by severe (MCAO; seeMaterials andMethods) model of ischemia is shown. C, Examples of stained slices illustrating the protective effect of D-JNKI1 (seeB). Scale bar, 1mm.D,
D-JNKI1 treatment of MCAO. D-JNKI1 (0.3mg/kg, i.p., 6 h after MCAO or 30min before it) does not significantly reduce the infarct volume. Con, Control. E, TAT-NR2B9c and D-JNKI1 are additively
protective in the severe MCAO stroke model. The graph shows the effects of combined peptide treatment of MCAO. Neither D-JNKI1 (0.3 mg/kg, i.p.) alone nor TAT-NR2B9c (7.5 mg/kg, i.p.)
alone reduced the infarct volume significantly, but combined treatment with both peptides gave significant protection (*p 0.05, Mann–Whitney test). For each treatment, 7–20 animals were
used. F, Examples of stained slices analyzed in E. Arrowheads indicate the infarcts.
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12 h (Borsello et al., 2003), we administered D-JNKI1 at 6 h after
the onset of ischemia. TAT-NR2B9c was given 30 min before
ischemia, because the therapeutic window for its use was un-
known. TAT-NR2B9c alone did not significantly reduce the vol-
ume of the infarct, but its combination with D-JNKI1 gave signif-
icant protection (Fig. 7E,F; supplemental Fig. S4, available at
www.jneurosci.org as supplemental material). Therefore, inhib-
iting NMDAR pro-death signals that are both dependent on the
NSC (p38) and independent of it (JNK) has synergistically pro-
tective effects in severe excitotoxic scenarios in vitro and in vivo.
Discussion
We show here that the NMDAR can be uncoupled from pro-
death signaling without interfering in models of synaptic
NMDAR-dependent neuroprotection and synaptic plasticity.
We also demonstrate that NMDAR signaling to JNK and p38 has
differing dependencies on neuron-specific signaling proteins and
the NR2B PDZ ligand, yet both contribute to excitotoxic death.
Targeting both pathways relies on separate approaches and pro-
vides effective protection from excitotoxicity in vitro and in vivo.
Failed clinical trials for stroke with NMDAR antagonists
Despite evidence fromanimal studies implicating theNMDAR in
ischemic brain damage, clinical trials of NMDAR antagonists for
stroke have failed because of poor tolerance and efficacy (Ikono-
midou and Turski, 2002; Muir, 2006). The important role of
NMDARs in the CNS may mean that for any antagonist, the
maximal tolerated dose is lower than the therapeutically effective
dose, because many unacceptable side effects are on-target ef-
fects. Evidence that NMDAR activity can exert a neuroprotective
effect has led to suggestions that it may even promote recovery
after reperfusion, and prevent delayed neuronal loss in the pen-
umbra (Albers et al., 2001; Ikonomidou and Turski, 2002). As
such, antagonists may be protective early in the insult but not
later on, which indicates a potential need for more specific anti-
excitotoxic strategies inwhich the effects on prosurvivalNMDAR
signaling are considered.
NMDAR-activated survival and death signals require spatially
distinct pools of Ca2
Activation of CREB is an important mediator of synaptic
NMDAR-dependent neuroprotection (Papadia et al., 2005). El-
evation ofCa2within the nucleus is important for full activation
of CREB-dependent gene expression and resultant neuroprotec-
tion (Hardingham et al., 1997, 2001a; Papadia et al., 2005), likely
because of the nuclear localization of CREB’s activator CaMKIV.
Nuclear Ca2 is also implicated in regulating memory consoli-
dation (Limba¨ck-Stokin et al., 2004), although whether this is via
CREB activation is not known. Thus, the nucleus is a major site
for physiological effects of NMDAR signaling. However, it does
not appear to play a role in excitotoxic cell death, because inhibi-
tion of nuclear Ca2/calmodulin signaling does not interfere
with NMDAR-dependent excitotoxic cell death (G. E. Harding-
ham, unpublished work). Another key NMDAR-activated pro-
survival signal, the PI3K–Akt pathway (Hetman and Kharebava,
2006), is likely to be activated by cytoplasmic Ca2 elevation,
because of the Ca2/calmodulin dependence of PI3K (Joyal et al.,
1997). Our results support this, because submembranousCa2 is
insufficient to trigger this pathway (Fig. 3D,F). On the other
hand, submembranous Ca2 transients are sufficient to activate
p38 signaling (Fig. 3D,E), which is a Ca2 pool not involved in
either prosurvival pathway. In contrast, pro-death signaling via
JNK may directly or indirectly involve Ca2 uptake into mito-
chondria and mitochondrial ROS production (Fig. 6). Ca2 up-
take into mitochondria has been shown to trigger ROS produc-
tion (Nicholls, 2004), suggesting that mitochondrial ROS
generation, potentially triggered by mitochondrial Ca2 uptake,
is a trigger for JNK signaling. Thus in cortical neurons, the
NMDAR-activated effectors of survival and death have very dif-
ferent spatial requirements for Ca2.
Role of the NR2B PDZ ligand in death signaling
The cell-permeable TAT-based NR2B9c fusion peptide protects
against excitotoxicity in vitro and in vivo by uncoupling NR2B
fromPSD-95 and downstream signalingmolecules such as nNOS
(Aarts et al., 2002) and p38MAP kinase (this study). Moreover, a
model of ischemia in which TAT-NR2B9c is highly neuroprotec-
tive is also responsive to a p38 inhibitor (Fig. 4H, I), suggesting
that TAT-NR2B9c acts in vivo by impairing pro-death p38 signal-
ing.Despite its efficacy, TAT-NR2B9cwould be of limited benefit
over conventional NMDAR antagonists if it impaired physiolog-
ical prosurvival and plasticity signaling. However, at therapeutic
concentrations, TAT-NR2B9c did not interfere with neuronal
culture models of these processes, nor did it affect basal network
activity. The fact that TAT-NR2B9c did not impair Ca2 influx
nor affect our model of NMDAR-dependent synaptic plasticity
suggests that interactions with the NR2B PDZ ligand may be
dispensable for plasticity, at least in the short term (although
effects on other models of plasticity cannot be ruled out).
Although global NMDAR blockade is not thought to be a
viable therapeutic option, a specific role for NR2B-NMDARs in
promoting cell death has been suggested (Liu et al., 2007) and
would enable this particular subtype of NMDAR to be targeted
without impairing prosurvival signaling, using the highly selec-
tive antagonists available. However, we recently found that
NR2B-NMDARs are capable of promoting both survival and
death signaling (Martel et al., 2008). Interestingly, NMDARs
have been reported to mediate p38 dephosphorylation in hip-
pocampal neurons (Krapivinsky et al., 2004;Waxman andLynch,
2005) mediated by NR2B-NMDARs (Waxman and Lynch,
2005), which is presumably a protective response that NR2B an-
tagonists would block.Moreover, NR2A-NMDARswere recently
shown to be capable of mediating excitotoxicity as well as protec-
tive signaling (von Engelhardt et al., 2007). Together, these stud-
ies indicate that NR2B-NMDARs and NR2A-NMDARs are both
capable of mediating survival and death signaling. Thus, the spe-
cific ability of NR2B-NMDARs andNR2A-NMDARs to promote
death and survival, respectively (Liu et al., 2007), may not apply
in all neuronal types at all developmental stages.
The inability of TAT-NR2B9c to uncouple the NMDAR from
JNK signaling (Fig. 4B) or impair JNK-mediated, NMDAR-
dependent death of NR-AtT20 cells (data not shown) indicates
that the JNK pathway does not rely heavily on the NR2B PDZ
domain. This is consistent with mitochondrial ROS production
being the trigger for this pro-death signal, rather than membrane-
proximal events. Our data implicate PKD as a potential
NMDAR-induced activator of JNK signaling by NMDAR activa-
tion (supplemental Fig. S3, available at www.jneurosci.org as
supplemental material). ROS can induce JNK signaling in
HEK293 cells by activating death-associated protein kinase
(DAPK), which in turn activates PKD (Eisenberg-Lerner and
Kimchi, 2007). The role of DAPK in JNK activation in ourmodel
awaits investigation, but, interestingly, DAPK has been found to
contribute to cerebral ischemic injury (Shamloo et al., 2005).
The neuroprotective effects of uncoupling NR2B from
PSD-95 provide a convincing explanation for the observation
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that Ca2 influx specifically through NMDARs promotes cell
death: i.e., that Ca2-dependent cell death is “source specific”
(Tymianski et al., 1993). However, this model is not universally
accepted: the idea that simply a highCa2 load is themain reason
for NMDAR-dependent cell death is supported by the fact that
cell death can be reconstituted in non-neuronal cells by express-
ing NMDARs in the absence of their associated signaling com-
plexes (Cik et al., 1993). Our data suggest that both models are
partially correct: efficient p38 signaling requires the NMDAR
signaling complex and could be viewed as source specific,
whereas JNK signaling does not. We did not examine calpain
activation in this study: although NMDAR activity is a typical
physiological activator of calpains in neurons, it is unclear
whether this is because of the highCa2 load triggered or because
of specific coupling via structural molecules. Interestingly, a pre-
cedent for the latter exists in the case of focal adhesion kinase,
which recruits both calpain and extracellular signal-regulated ki-
nase (ERK), resulting in ERK-mediated phosphorylation and ac-
tivation of calpain (Wells et al., 2005).
Ca2 influx dependent on intense synaptic NMDAR activa-
tion iswell tolerated by hippocampal neurons, whereas activation
of extrasynaptic NMDARs, either on their own or in the presence
of synaptic NMDAR activation, causes a loss of mitochondrial
membrane potential and cell death (Hardingham et al., 2002).
These findings have been recapitulated by others in cortical neu-
rons (Leveille et al., 2005), raising the possibility that this is a
general CNS phenomenon. At first glance, these observations are
at apparent odds with the protective effects of TAT-NR2B9c, if
we assume that TAT-NR2B9c exerts its effect by uncoupling syn-
aptic NMDARs from PSD-95 and nNOS activation. However,
TAT-NR2B9c could conceivably be exerting its effects on extra-
synaptic as well as synaptic NMDARs. Although immunohisto-
chemical studies show PSD-95 to be mostly in synaptic puncta,
this does not rule out a more diffuse distribution of PSD-95 at
extrasynaptic sites, interacting with extrasynaptic NMDARs.
Moreover, extrasynaptic clusters of PSD-95 have been observed
in hippocampal neurons at a frequency of almost half that of
synaptic clusters (Carpenter-Hyland and Chandler, 2006). An-
other possibility is that extrasynaptic NR2 PDZ ligands form in-
teractions with a death effector other than PSD-95, which are also
disrupted by TAT-NR2B9c.
Even if TAT-NR2B9c is acting specifically on synaptic
NMDARs, it could be that synaptic NMDAR signaling to p38
contributes to cell death in the context of a neuron experiencing
chronic extrasynaptic NMDAR activity. There is a good deal of
evidence implicating p38 as a mediator of NMDAR-dependent
excitotoxicity (Kawasaki et al., 1997; Cao et al., 2004; Rivera-
Cervantes et al., 2004; Molz et al., 2008). However, nontoxic
episodes of NMDAR activity (e.g., induced by bicuculline or low
doses of NMDA) can also activate p38, indicating that p38 only
contributes to toxicity in certain contexts. Thus, it is possible that
synaptic NMDAR signaling to p38 is tolerated during an episode
of synaptic activity; however, it may be harmful when induced in
a cell under stress from chronically elevated levels of extracellular
glutamate (e.g., after an ischemic episode).
Another intriguing question surrounding the action of TAT-
NR2B9c is whether it is acting via pathways other than simply
inhibiting p38 activation. This seems likely, because the protec-
tive effect of TAT-NR2B9c is at least as good as that of p38 inhib-
itors, despite not completely inhibiting p38 activation byNMDA.
Other pro-death pathways may be inhibited, for example, other
toxic actions of NO production. Alternatively, a lack of protein
interactions at the NR2 PDZ ligand may facilitate the binding of
other signaling molecules that promote a prosurvival effect.
Future therapy combinations in stroke trials?
Therapies that target downstream death pathways in combina-
tion may be effective in blocking NMDAR pro-death signaling,
such as a combination of TAT-NR2B9c and D-JNKI, both of
which are effective if administered after the commencement of
ischemia (Aarts et al., 2002; Borsello et al., 2003). Although in our
model, the SAPKs p38 and JNK are the main mediators of exci-
totoxicity, othermediators of ischemic cell death include calpain-
dependent cleavage of the Na/Ca2 exchanger (Bano et al.,
2005) and activation of TRPM7 channels (Aarts et al., 2003). The
precise pathway(s) that mediate ischemic brain damage may de-
pend on the neuronal subtype, the severity and duration of the
episode, and the position of the neuron within the ischemic zone
(core or penumbra). Therefore, it may be that additional mole-
cules that target calpain or TRPM7 activation may be yet more
effective as part of a mixture of antideath signaling drugs. Their
use, where appropriate, in conjunction with the thrombolytic
drug tissue plasminogen activator, may aid in rapid drug delivery
to the site of insult.
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